As of May 29
| -1.87 / -2.34%|
The 8 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 98.00, with a high estimate of 127.00 and a low estimate of 70.00. The median estimate represents a +25.30% increase from the last price of 78.21.
The current consensus among 9 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.